



Expanding **TREATMENT OPTIONS**
for **CANCER PATIENTS**

ANNUAL IMPACT SHEET 2014

MISSION & VISION

MAIN ACTIVITIES

Research projects
Patient support

TEAM

FINANCIAL PERFORMANCE




1 in 3 men
will develop cancer



1 in 4 women
will develop cancer

MAIN ACTIVITIES

1. Research Projects



PRECLINICAL PROJECTS (total 11.9%)

- Cryoablation and non-toxic products (7.45%)
- Gloriosa superba extract (1.77%)
- Radiotherapy & Immune Response (2.68%)

CLINICAL PROJECTS (total 52.07%)

- Nitroglycerine patch & radiotherapy (<1%)
- Metzolimos (3.20%)
- B-AHEAD 3 (5.37%)
- Artesunate (1.11%)
- Fluvabrex (<1%)
- Ketorolac (13.87%)
- Ultra low dose chemotherapy (2.04%)
- Vagus Nerve stimulation (6.38%)
- Boost your mind (8.62%)
- Adoptive T-cell therapy (10.71%)
- EFFECT - EEffectiveness of Endometrial Cancer Treatments in collaboration with the Belgian Cancer Registry (1.74%)
- Verelst Uterine Fund in collaboration with KU Leuven, Belgium (34.29%)

Our vision

- As a society, we need to ensure that no treatment option is left untapped.

Our dual mission

- Funding promising breakthrough therapies which are commercially neglected
- Free comprehensible cancer information

2. Patient Support

In 2010-2014 434 patients received information via info@anticancerfund.org.

	Total
Guides for patients with general information	10
Guides for patients with information per cancer type (ESMO)	16
Information sheets for patients on therapies (mainstream & non-mainstream)	267

ACF-supported research projects are currently scheduled to include over 544 patients up to end 2014.



Endometrial cancer:
10 patients



Colorectal cancer:
10 patients



Lung cancer:
60 patients



Liver cancer:
15 patients



Breast cancer:
320 patients



Osteosarcoma:
26 patients



Melanoma:
12 patients



All cancer types:
56 patients



Optic-pathway glioma:
35 patients

For a detailed list of our projects, contact us or consult our [website](http://www.anticancerfund.org):

NEW PROJECTS

	Country	Project area	Budget
B-AHEAD 3, a 2 day calorie/energy restricted diet combined with chemotherapy	UK	ADVANCED BREAST CANCER - randomised phase II trial	€ 263,000
Metzolimos, a combination of 4 repurposed drugs	France	OSTEOSARCOMA (BONE TUMOR) - phase Ib trial	€ 165,000
Nitroglycerine patch combined with radiotherapy	The Netherlands	NON-SMALL CELL LUNG CANCER - phase II trial	€ 78,000
Evaluating oral Artesunate	Belgium	HEPATOCELLULAR CARCINOMA (LIVER CANCER) - phase I trial	€ 62,000

New project - ReDO - Repurposing Drugs in Oncology

The Repurposing Drugs in Oncology (ReDO) project is a collaboration with the US not-for-profit organisation Global Cures. The aim of the project is straightforward – to identify a range of existing non-cancer drugs which show strong evidence of anti-cancer activity and which have the potential for clinical use. There is a broad spectrum of drugs that the project has identified, many of them available as cheap generics, including antibiotics, antifungals and antiparasitics. Taking evidence from a variety of sources, the ReDO project has reviewed, summarised and published the results in peer-reviewed journals.

EVENT - Roundtable conference - TIL in ovarian cancer

In June 2014 a round table conference was organized in Brussels by the Anticancer Fund aiming to cooperate and share expertise to efficiently extend the successful results of adoptive TIL transfer-therapy in melanoma to ovarian cancer. Adoptive TIL therapy has a profound better complete response rate compared to all other treatments for advanced melanoma and results in durable responses. Two projects were initiated as a result of this meeting: 'Immunotherapy by adoptive T cell infusion in the event of advanced ovarian cancer' (University Hospital Herlev, Denmark) and 'Combined Chemo- and Adoptive T cell-therapy (ACT) as treatment for recurrent epithelial ovarian carcinoma' (Leiden University Medical Centre, the Netherlands). The meeting and the project were supported by OvaCure (a Danish non-profit organization focused on the fight against ovarian cancer).

OUR TEAM with a focus on scientists and medical doctors

We welcomed 4 new team members in 2014.



An Van Nuffel, Ph.D.
Program manager
immunotherapy



Fabienne Van de Keere, Ph.D.
Expert cellular immunotherapy



Sarah Vandenbroek
Team Assistant




Pan Pantziarka, Ph.D.
Expert Drug Repurposing

FINANCIAL PERFORMANCE

Expenses in 2014

■ INFORMATION (24,4%)	€ 402,294
■ COMMUNICATION & FUNDRAISING (13,1%)	€ 217,173
■ ADMINISTRATION (7,4%)	€ 122,413
■ RESEARCH PROJECTS (55,1%)	€ 910,771
TOTAL	€ 1,652,651



TOTAL EXPENDITURE for 2014 was € 1,652,651.

This expenditure is divided mainly between information & communication activities and the amount spent on supporting our research projects.

Amount spent on

■ INFORMATION: € 402,294

This expenditure covers two main areas:

1. website costs, including updating information and adding new information (€ 308,211)
2. the costs of maintaining our patient support via info@anticancerfund.org (€ 94,083)

■ COMMUNICATION AND FUNDRAISING: € 217,173

This includes a dedicated full-time fundraising employee.

■ ADMINISTRATION: € 122,413

This covers the general administrative support at the Anticancer Fund.

■ RESEARCH PROJECTS: € 910,771

This covers all costs, including the personnel cost of the ACF employees managing specific projects, of the preclinical projects, the clinical projects, the Verelst Uterine Fund and the EFFECT project.

Total amount spent: € 1,650,000 well spent in the fight against cancer!



Address Anticancer Fund, Boechoutlaan 221,
1853 Strombeek-Bever, Belgium

Tel. +32 (0)2 268 48 16

Email info@anticancerfund.org

Website www.anticancerfund.org

Support us BE79 5230 8061 2533 - BIC TRIOBEBB